Glucagon-Like Peptide 1

Schott Pharma Invests Over €100M in New Sterile Cartridge Facility at Hungary Site

3 days ago talkbio0Tagged Automation, Diabetes, expansion, Glucagon-Like Peptide 1, Hungary, Impacts, Environmental, Investments, Lukácsháza, Manufacturing, Pharma, pharma packaging, RTU cartridges, Schott, sterile cartridge facility

Schott Pharma; Hungary; sterile cartridge facility; €100 million investment; RTU cartridges; pharma packaging; manufacturing expansion; Lukácsháza; GLP-1 drugs; diabetes; automation; environmental impact

Novo Nordisk and Septerna Forge $2.2B+ Collaboration on Oral Obesity and Diabetes Drugs

3 weeks ago talkbio0Tagged cardiometabolic diseases, Collaboration, Diabetes Mellitus, Non-Insulin-Dependent, G-Protein-Coupled Receptors, Gastric Inhibitory Polypeptide, Glucagon Receptor, Glucagon-Like Peptide 1, Nordisk, Obesity, oral drugs, Septerna, small molecule therapies

Novo Nordisk; Septerna; GPCR; oral drugs; obesity; type 2 diabetes; cardiometabolic diseases; GLP-1; GIP; glucagon receptors; small molecule therapies; collaboration; pharmaceuticals

Compounders just lost their case to put obesity drug tirzepatide back in shortage

1 month ago talkbio0Tagged Drug Shortage, Eli, Eli Lilly, Facilities Association, Glucagon-Like Peptide 1, Legal Case, Mounjaro, OFA, tirzepatide, United States Food and Drug Administration, Zepbound

Tirzepatide, compounding, FDA, drug shortage, Eli Lilly, Zepbound, Mounjaro, legal case, Outsourcing Facilities Association (OFA), GLP-1 medications

Cigna’s Evernorth unveils 2 new programs aimed at GLP-1s

1 month ago talkbio0Tagged Cigna 's, Enhance (action), GLP-1s, Glucagon-Like Peptide 1, Pharmaceutical Services, Pharmacy facility, Programs - Publication Format

Programs – Publication Format, Glucagon-Like Peptide 1, Cigna ‘s, GLP-1s, Pharmacy facility, Enhance (action), Pharmaceutical Services

Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

2 months ago talkbio0Tagged Approved, competition, eli lilly, Glucagon-Like Peptide 1, Market, Nordisk, Novo, Obesity, Oral cavity, Pressure- physical agent, semaglutide, United States Food and Drug Administration

Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

2 months ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil

2 months ago talkbio0Tagged Brazil, Claros facility, Diabetes, Glucagon-Like Peptide 1, Investments, Montes, Nordisk, Obesity, Ozempic, pharmaceutical manufacturing, production, Wegovy

Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing